NICE Increases Options For Hyperkalemia Patients In England
Vifor’s Veltassa & AstraZeneca’s Lokelma Get Green Light
Executive Summary
Patients with high levels of blood potassium in England have two more options for treating their condition after NICE reversed its earlier negative recommendations.